BOSTON — An investigative small-diameter defibrillation lead for implantable cardioverter-defibrillators has exceeded its safety and efficacy expectations in a pivotal clinical trial. The LEADR trial implanted OmniaSecure leads in 643 patients. It found that almost 98% of the experimental leads were successfully implanted, and 99.5% were placed precisely in the desired location in the right …
